Perioperative Repurposed Drugs To Reduce Metastases

Peri-operative medications that reduce metastatic risk should be regarded as standard of care. With a simple, low-cost intervention, we can prevent avoidable deaths. Choosing not to offer this evidence-based treatment is, in my view, ethically indefensible and approaches medical malpractice.

The proposed mechanisms by which surgery may promote metastatic spread, along with the interventions discussed in this guide, are summarized in Figure 1.

Figure 1. Perioperative repurposed drugs to reduce metastases.

Why Surgery May Increase Metastatic Risk

The phenomenon of postsurgical distant recurrence is common across many cancers, including breast cancer, non-small cell lung cancer, osteosarcoma, and others. Among solid tumors, early distant recurrence following surgical resection shows a remarkably consistent pattern, yet little sustained effort has been made to address this problem.

Metastasis — the spread of cancer cells from a primary tumor to distant organs — involves a complex sequence of steps known as the metastatic cascade. (1) While the process is highly inefficient, with most cancer cells failing to complete all stages, a small number of cells may succeed.

Isolated cancer cells that break away from the primary tumor must first breach the connective tissue immediately surrounding the cancer. Once free, the next step is to enter a blood or lymphatic vessel, a process that requires the cancer cell to secrete enzymes that degrade the vessel’s basement membrane. Once in circulation, the cell faces turbulence from fast-moving blood, which can damage and destroy it. It must also avoid detection and destruction by white blood cells circulating in the bloodstream. To complete its voyage, the cancer cell must adhere to the lining of the blood vessel, degrade the basement membrane and exit the vessel, and burrow into the surrounding connective tissue to reach its final destination: the target organ. There, it begins to multiply, forming a growing colony that serves as the foundation of a new metastatic tumor. This entire sequence of events must occur quickly, as these cells have a limited lifespan.

A groundbreaking 2009 study published in the Annals of Surgery reported that cancer surgery can create a physiological environment that significantly reduces the barriers cancer cells normally face. (2) Surgical removal of a tumor almost always disrupts the structural integrity of the tumor and the blood vessels feeding it. This disruption can lead to cancer cells spilling into the bloodstream or seeding directly into the chest or abdominal cavity. (3,4) This alternate route created by surgery can significantly simplify the path to metastasis.

Cancer surgery triggers increased production of inflammatory cytokines (chemical signaling molecules) such as interleukin-1 and interleukin-6. (5,6) These signaling molecules elevate the activity of cyclooxygenase-2 (COX-2), a highly potent inflammatory enzyme. COX-2 promotes cancer growth and metastasis by stimulating angiogenesis, the formation of new blood vessels that supply nutrients to tumors. (7,8) It also increases cancer cell adhesion to blood vessel walls, thereby enhancing the cells’ ability to spread to distant sites.

Once a circulating tumor cell reaches its destination, it must multiply to approximately 1 billion cells before becoming clinically detectable — roughly equivalent to 1 gram of tumor or 1 centimeter in diameter, as shown in Figure 2. Cancer doubling time refers to how long it takes for a tumor to double in volume or for the number of cancer cells to double. This metric is critical for understanding how quickly a cancer grows and can influence prognosis, treatment decisions, and the timing of metastatic spread. Across cancers studied, doubling times have been reported to range from as little as 44 days to more than 1,800 days, with averages in some studies between 200 and 325 days. (9-11) This helps explain why metastases from slow-growing tumors may not appear until 10 years or more after definitive surgery. To reach 1 billion cells, about 30 doublings are required.

One study compared survival among women with breast cancer who underwent surgery with survival among those who did not. (12) As expected, surgery substantially improved early survival. However, further analysis of the data revealed a spike in mortality around year eight in the surgery group — a pattern not observed in the non-surgery group. (12) A worthwhile strategy to reduce this long-term risk is to identify the mechanisms by which surgery may promote metastasis and develop a comprehensive plan to counteract each of them.

Figure 2. Tumor burden and growth kinetics

Modified Citrus Pectin

Cancer cells that break away from the primary tumor rely on adhesion to increase their ability to form metastases in distant organs. These cells must cluster together to form colonies capable of expansion and growth; therefore, an individual cancer cell may be less likely to establish a metastatic tumor on its own. Adhesion molecules, such as galectin-3, play a key role in facilitating this clustering. Circulating tumor cells (CTCs) also use galectin-3 on their surface to latch onto the lining of blood vessels — a critical step in the metastatic process. (13)

Modified citrus pectin (MCP) has shown potential in reducing perioperative cancer metastases by targeting mechanisms involved in tumor cell adhesion and dissemination. MCP binds to galectin-3, a protein overexpressed in metastatic cancers that promotes tumor cell aggregation, adhesion to blood vessels, and tissue invasion. (13-15) By inhibiting galectin-3, MCP may reduce cancer cell clustering or attachment to tissues, thereby limiting metastatic spread. (13)

Galectin-3 and Metastatic Adhesion

Galectin-3 appears central to several perioperative mechanisms that promote metastatic spread, including:

• Tumor cell adhesion to endothelium

• CTC clustering

• Platelet–tumor interactions

• Metastatic implantation

• Immune evasion

• Angiogenesis

These are exactly the processes that are amplified after surgery.

By inhibiting galectin-3, MCP theoretically may:

• Reduce metastatic seeding

• Reduce CTC adhesion

• Impair metastatic niche formation

• Decrease platelet shielding of tumor cells

• Preserve immune surveillance

This is biologically highly plausible.

Potential Perioperative Synergies

MCP fits naturally alongside other antimetastatic perioperative strategies, such as:

• Propranolol

• COX-2 inhibition (celecoxib)

• Melatonin

• Omega-3 fatty acids

• Low-glycemic nutrition

• Vitamin D optimization

• Perioperative fasting strategies

• Statins

• Metformin

These interventions target overlapping aspects of:

• Inflammation

• Stress signaling

• Coagulation

• Immune dysfunction

• Metastatic implantation

In vitro studies showed that MCP inhibited breast and prostate cancer cell adhesion, migration, and invasion by up to 95% in assays mimicking metastasis.

In a murine model, Nangia-Makker et al. demonstrated that oral administration of MCP significantly inhibited tumor growth, angiogenesis, and spontaneous metastasis of human breast and prostate cancer cells — effects attributed to galectin-3 blockade. (16)

In rats with colon cancer, high-dose MCP reduced the incidence of liver metastases by 40% (p = 0.008) and tumor volume by 54% (p = 0.003). (15)

In prostate cancer models, MCP led to a 50% reduction in lung metastases and an 89% decrease in metastatic colony size. Melanoma studies reported more than 90% fewer lung metastases in MCP-treated mice. In patients with biochemically relapsed prostate cancer, MCP has been associated with limited disease progression. (17)

However, clinical trials are still needed to confirm MCP’s effectiveness in preventing perioperative metastases in humans.

Dosing and Timing of MCP

Practical Strategy

Although no standardized protocol exists, many integrative practitioners use MCP

beginning 1 to 2 weeks before surgery and continuing through recovery.

Typical dosing: 5 g taken two to three times daily, if tolerated.

Galectin-3 inhibition is likely best maintained through continuous rather than intermittent exposure:

• Divided dosing is preferred

• Consistent exposure may be more important than achieving peak levels

MCP is typically taken:

• On an empty stomach (30 minutes before meals or 2 hours after eating)

• Between meals

• At least 2 hours apart from medications and mineral supplements

Please refer to this post on Modified Citrus Pectin for additional dosing guidance.

Propranolol and COX-2 Inhibitors

Perioperative COX-2 inhibition — especially when combined with β-blockers — may attenuate postoperative immune suppression and reduce the risk of metastatic progression. Clinical trials suggest that this combined therapy can improve biomarkers associated with tumor metastasis, immune function, and inflammation, and may also enhance long-term disease-free survival in certain types of cancer. (18-20)

Unlike nonselective NSAIDs, which inhibit both COX-1 and COX-2, selective COX-2 inhibitors do not significantly increase the risk of perioperative bleeding or blood loss. (21) While generally considered safe in the perioperative setting, COX-2 inhibitors still raise safety concerns — particularly related to cardiovascular risk and unresolved controversies surrounding their long-term use — which require careful evaluation. (22) Their use should be limited to patients whose cardiovascular profile and overall clinical status support a favorable risk-benefit balance.

Beta-adrenergic signaling is implicated in the postsurgical metastatic process, and numerous in vivo studies have reported that perioperative propranolol is associated with a reduced rate of metastases. (23) In a phase 2 randomized trial, Hiller et al. evaluated the use of preoperative β-blockade with propranolol on metastatic tumor biomarkers in women undergoing surgery for breast cancer. (24) In this triple-blind, placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80-160 mg daily) or placebo (n = 30) for seven days prior to surgery.

A 2025 systematic review of 31 studies (7 RCTs, 4 systematic reviews, and 20 meta‑analyses) concluded that propranolol may improve cancer outcomes, especially when given around the time of surgery to reduce recurrence risk. (25)

Propranolol downregulated mesenchymal gene expression in the primary tumor and altered the intratumoral recruitment of neutrophils, natural killer cells, and dendritic cells. It also increased tumor infiltration by CD68+ macrophages (consistent with M1 polarization) and CD8+ T cells.

Because surgery increases the release of pro-inflammatory mediators that may promote metastasis, combining propranolol with a COX-2/prostaglandin E2 (PGE2) inhibitor, such as ketorolac or etodolac, may offer synergistic benefits in the perioperative setting. (26,27)

NCT02596867 is a phase 2 open-label window-of-opportunity trial in newly diagnosed breast cancer. (28) Propranolol, at a dose of 1.5 mg/kg twice daily (BID), is administered for three weeks before surgical resection. The primary outcome is a reduction in the proliferative index (Ki-67); secondary outcomes relate to safety, toxicity, and adherence.

NCT00888797 is a phase 3 randomized, placebo-controlled trial of perioperative propranolol and etodolac (a COX-2 inhibitor) in colorectal cancer patients undergoing resection (COMPIT trial). (28) Patients in the treatment arm receive etodolac 800 mg BID throughout the intervention, along with a tapering schedule of propranolol: 20 mg BID for five preoperative days, 80 mg BID on the day of surgery, 40 mg BID during the first postoperative week, and 20 mg orally BID during the second postoperative week.

The primary endpoint is the rate of local and distant recurrence at five years. Preliminary results indicated that adverse event rates were similar between groups. However, intent-to-treat analyses at five-year follow-up showed recurrence in 2 of 16 (12.5%) treated patients compared with 9 of 18 (50%) in the placebo group (p = 0.033). (29)

In a landmark study, the incidence of bone metastases in breast cancer patients who received COX-2 inhibitors for at least six months after diagnosis was compared with that of patients who did not take a COX-2 inhibitor. (30) Those taking a COX-2 inhibitor were nearly 80% less likely to develop bone metastases.

Forget and colleagues reported on a retrospective analysis of breast cancer patients treated with conservative surgery, with or without intraoperative NSAIDs (ketorolac or diclofenac). (31) Patients treated pre-incisionally with ketorolac (20-30 mg) or diclofenac (75 mg) showed improved disease-free survival (HR = 0.57; 95% CI, 0.37-0.89; p = 0.01) and overall survival (HR = 0.35; 95% CI, 0.17-0.70; p = 0.03) compared with those not treated with NSAIDs. (26) However, these findings were not replicated in a prospective randomized trial. (32)

Cimetidine

Cimetidine, an H2 blocker, has shown promising results in improving survival rates for colorectal cancer patients when administered perioperatively. A key study by Adams and Morris demonstrated that a seven-day perioperative course of cimetidine (400 mg BID for five days before surgery and two days after) increased three-year survival from 59% to 93% in 34 patients, although this result was not statistically significant (p = 0.17). (33)

Matsumoto performed a similar study in 64 patients undergoing colorectal surgery. (34) One group received cimetidine 800 mg along with 5-fluorouracil 150 mg orally each day for approximately one year, beginning two weeks after surgery. The control group received 5-fluorouracil alone. After a mean follow-up of 31 months, the 3.9-year survival rate was 96.3% in patients treated with cimetidine, compared with 68% in the control group (p = 0.02).

Subsequent research by the same group provided even more compelling evidence for cimetidine’s anticancer effects. A longer-term study involving the same cohort demonstrated that the observed benefits were sustained over a 10-year period. (35) The cumulative 10-year survival rate was 84.6% in the cimetidine group versus only 49.8% in controls (p < 0.0001). This dramatic difference in long-term outcomes suggests that cimetidine’s benefits were more than temporary; they reflected genuine changes in cancer progression and patient prognosis.

Mechanistic studies suggest that cimetidine’s anticancer effects may result from its ability to inhibit E-selectin expression on vascular endothelial cells. Researchers demonstrated that cimetidine could block the adhesion of colorectal tumor cell lines to endothelial monolayers in vitro and suppress liver metastasis in nude mice. (36) Molecular analyses showed that cimetidine downregulated E-selectin expression without altering E-selectin mRNA levels or affecting nuclear factor κB translocation, suggesting a post-transcriptional mechanism. (36) Importantly, other H2 receptor antagonists, including famotidine and ranitidine, did not produce similar effects, suggesting that cimetidine’s anticancer activity may involve mechanisms beyond histamine H2 receptor blockade. (36,37)

A comprehensive 2012 Cochrane Review analyzed data from six randomized clinical trials involving H2 receptor antagonists as adjuvant treatments for resected colorectal cancer. (27) The review pooled data from 1,229 patients and found a trend toward improved survival when H2 receptor antagonists were used as adjuvant therapy (HR = 0.70; 95% CI, 0.48-1.03; p = 0.07). When analyzing only the five cimetidine trials with 421 patients, the meta-analysis found a statistically significant improvement in overall survival (HR = 0.53; 95% CI, 0.32-0.87). The authors concluded that cimetidine appears to confer a survival benefit when given as an adjunct to curative surgical resection of colorectal cancer.

The evidence strongly supports the integration of cimetidine into treatment protocols for appropriately selected colorectal cancer patients, particularly those with node-positive disease and tumors expressing high levels of sialyl Lewis antigens. Clinical studies have used various cimetidine dosing regimens, with the most successful trials administering 800 mg orally each day. The original Japanese study initiated treatment two weeks after surgery and continued for one year. The success of cimetidine in colorectal cancer has not been reproduced in other cancers. Because cimetidine increases plasma levels of propranolol, the propranolol dose should be carefully adjusted. (38)

Perioperative Protocol Considerations

The optimal perioperative pharmacologic approach to reducing metastatic disease remains unknown, as does the ideal duration of therapy. However, given a favorable risk-benefit ratio, MCP combined with propranolol should be considered for most patients. MCP at 10-15 g/day should be initiated at least five days before surgery and continued for six to 12 months postoperatively.

Propranolol at a dose of 40 to 80 mg BID is recommended to maintain a resting pulse of approximately 60 to 70 bpm. The propranolol dose should be adjusted carefully in patients also taking cimetidine, and the anesthesiologist should be informed that the patient is taking a beta-blocker. Postoperatively, patients should continue a tapering dose of propranolol for two to four weeks.

Perioperative COX-2 inhibitors should be considered in patients at high risk of metastatic spread who have a favorable cardiac profile. Cimetidine should be considered in patients undergoing surgery for colorectal cancer at a dose of 800 mg/day beginning at least five days before surgery and continuing for up to one year postoperatively. This regimen should be combined with MCP 10-15 g/day.

Medical Disclaimer: The discussion of repurposed medications and nutraceuticals in this article is intended to review the scientific literature and does not constitute a recommendation for self-treatment. Decisions regarding the use of off-label therapies should be made in consultation with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan. Please see the full Medical Disclaimer on the introductory page to Marik’s Cancer & Metabolic Healing Playbook.

References

1. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10 Suppl 1(Suppl 1):S2.

2. van der Bij GJ, Oosterling SJ, Beelen RH, Meijer S, Coffey JC, van Egmond M. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009;249(5):727–34.

3. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000;232(1):58–65.

4. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10(8):972–92.

5. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg. 1992;79(8):757–60.

6. Wu FP, Sietses C, von Blomberg BME, van Leeuwen PA, Meijer S, Cuesta MA. Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum. 2003;46(2):147–55.

7. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705–16.

8. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther. 2003;2(1):1–7.

9. Weiss W. Implications of tumor growth rate for the natural history of lung cancer. J Occup Med. 1984;26(5):345–52.

10. von Fournier D, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. Cancer. 1980;45(8):2198–207.

11. Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, Kaneko M. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol. 1994;24(4):199–204.

12. Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer. 2001;85(4):490–2.

13. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344(14):1788–91.

14. Picot-Allain MCN, Neergheen VS. Pectin a multifaceted biopolymer in the management of cancer: A review. Heliyon. 2023;9(11):e22236.

15. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol. 2008;14(48):7386–91.

16. Nangia-Makker P, Hogan V, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94(24):1854–62.

17. Keizman D, Frenkel M, Peer A, et al. Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: long-term results of a prospective phase II study. Nutrients. 2023;15(16):3533.

18. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15(7):2042–52.

19. Haldar R, Ricon-Becker I, Radin A, et al. Perioperative COX-2 and β-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial. Cancer. 2020;126(17):3991–4001.

20. Shaashua L, Shabat-Simon M, Haldar R, et al. Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase II randomized trial. Clin Cancer Res. 2017;23(16):4651–61.

21. Teerawattananon C, Tantayakom P, Suwanawiboon B, Katchamart W. Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):520–8.

22. Kharasch ED. Perioperative COX-2 inhibitors: knowledge and challenges. Anesth Analg. 2004;98(1):1–3.

23. Lee JW, Shahzad MMK, Lin YG, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009;15(8):2695–702.

24. Hiller JG, Cole SW, Crone EM, et al. Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. Clin Cancer Res. 2020;26(8):1803–11.

25. O’Logbon J, Tarantola L, Williams NR, Mehta S, Ahmed A, Davies EA. Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. J Cancer Res Clin Oncol. 2025;151(7):212.

26. Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014;113(Suppl 1):i82–i87.

27. Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev. 2012;(8):CD007814.

28. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29(19):2635–44.

29. Ricon-Becker I, Haldar R, Simon MS, et al. Effect of perioperative COX-2 and beta-adrenergic inhibition on 5-year disease-free-survival in colorectal cancer: A pilot randomized controlled Colorectal Metastasis PreventIon Trial (COMPIT). Eur J Surg Oncol. 2023;49:655–61.

30. Valsecchi ME, Pomerantz SC, Jaslow R, Tester W. Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clin Breast Cancer. 2009;9(4):225–30.

31. Forget P, Vandenhende J, Berliere M, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–5.

32. Forget P, Bouche G, Duhoux FP, et al. Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PloS One. 2019;14(12):e0225748.

33. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994;344(8939-8940):1768–9.

34. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet. 1995;346(8967):115.

35. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002;86(2):161-167.

36. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res. 2000;60(14):3978–84.

37. Eaton D, Hawkins RE. Cimetidine in colorectal cancer: are the effects immunological or adhesion-mediated? Br J Cancer. 2002;86(2):159–60.

38. Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17(Suppl 1):51s–7s.